CVRX

Analyst Ratings on Healthcare Stocks: Analysts have expressed bullish sentiments towards Adverum Biotechnologies, Gilead Sciences, and CVRx, with Adverum receiving a Strong Buy consensus and a price target of $30.00, while Gilead has a Moderate Buy rating with a target of $105.81, and CVRx also holds a Strong Buy with a target of $19.40.

Performance Insights: The analysts' rankings indicate varying success rates, with Mizuho Securities' Salim Syed and Graig Suvannavejh both having lower average returns, while Chase Knickerbocker from Craig-Hallum boasts a higher average return and success rate in the healthcare sector.

New Study Findings: CVRx presented new real-world evidence at the THT conference showing that Barostim implantation significantly reduces hospital visits and length of stay for heart failure patients, with reductions of 86% in all-cause visits and 85% in heart-failure related visits.

Barostim Technology Overview: The Barostim System is an FDA-approved implantable device that uses neuromodulation to alleviate heart failure symptoms by restoring balance to the autonomic nervous system.

New Evidence Presentation: CVRx presented new real-world evidence at the Technology and Heart Failure Therapeutics conference, showing significant reductions in hospital visits and length of stay after Barostim implantation, as published in the Journal of Cardiac Failure.

Company Commitment: Dr. Philip Adamson emphasized the importance of this study in supporting the clinical utility of Barostim and highlighted CVRx's dedication to developing strong clinical and economic data for their therapy.

U.S. Stock Futures and Skechers Performance: U.S. stock futures showed mixed results, with Dow Jones futures slightly up. Skechers U.S.A. shares fell 12.1% in pre-market trading after reporting disappointing fourth-quarter earnings and issuing lower-than-expected first-quarter guidance.

Other Stocks Declining: Several other companies also saw significant declines in pre-market trading, including BILL Holdings (-28.4%), e.l.f. Beauty (-25.2%), and Cyngn Inc. (-22%), following poor financial forecasts or results.

Pinterest's Financial Performance: Pinterest, Inc. shares surged 20.5% in pre-market trading after reporting fourth-quarter revenue of $1.15 billion, exceeding estimates, although earnings per share fell short of expectations.

Market Movements: Several stocks experienced significant pre-market trading changes, with FitLife Brands gaining 138.2% due to a stock split, while Nikola Corporation dropped 29.7% amid bankruptcy concerns.

Analyst Ratings Overview: Recent ratings for CVRx show a mix of bullish and somewhat bullish sentiments, with 3 analysts rating it as bullish and 1 as somewhat bullish in the last 30 days. The average price target has increased to $21.75, reflecting a positive shift in expectations.

Company Financial Performance: CVRx reported a revenue growth rate of 27.23% over the past three months, although it lags behind industry peers. The company maintains a lower debt-to-equity ratio, indicating healthier financial management despite challenges in asset utilization.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and timely updates.

Analyst Ratings: Craig-Hallum analyst Chase Knickerbocker maintains a Buy rating on CVRx, with an average price target of $20.50, indicating a potential upside of 34.07% from its current share price of $15.29.

Insider Activity: Recent corporate insider activity shows negative sentiment towards CVRx, with insiders selling shares, including a notable sale by the Chief Marketing Officer in November 2024.

Top Stock Picks: Analysts have identified three stocks as Strong Buys: CVRx (CVRX) with a 36% upside, 89bio (ETNB) with a 201% upside, and Flux Power Holdings (FLUX) with a 147% upside based on recent ratings and price targets.

Investment Tools: TipRanks offers tools like the Smart Score and Analyst Top Stocks to help investors make informed decisions by tracking top-performing stocks and analyst recommendations.

Analyst Rating and Price Target: Frank Takkinen from Lake Street has maintained a Buy rating on CVRx with a price target of $19.00, while the analyst consensus suggests a Strong Buy with an average target of $21.00.

Insider Activity and Sentiment: Recent insider activity indicates negative sentiment towards CVRx, as 13 insiders have sold shares recently, including a notable sale by the Chief Marketing Officer in November 2024.

CVRx Financial Results Announcement: CVRx, Inc. will release its fourth quarter 2024 financial and operating results on February 4, 2025, followed by a conference call at 4:30 PM ET, which will be accessible via webcast and telephone.

About Barostim™ Device: CVRx's Barostim™ is an FDA-approved neuromodulation device for heart failure patients that aims to restore autonomic nervous system balance through electrical pulses to carotid artery baroreceptors.

Analyst Ratings: William Blair analyst Margaret Kaczor maintains a Buy rating on CVRx with a price target of $17.62, while the overall analyst consensus suggests a Strong Buy with an average price target of $18.44.

Insider Activity: Recent corporate insider activity indicates negative sentiment towards CVRx, with insiders selling shares at a higher rate compared to earlier this year, including a notable sale by the Chief Marketing Officer in November 2024.

Analyst Ratings Overview: In the last quarter, 7 analysts rated CVRx with a majority being bullish, showing an increase in price targets averaging $18.00, reflecting an 18.89% rise from previous estimates.

Financial Performance Insights: CVRx reported a revenue growth of approximately 27.23%, but faced challenges with lower growth compared to industry peers, while maintaining a strong net margin and a conservative debt-to-equity ratio.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and timely updates.

William Blair Upgrade: William Blair has upgraded CVRx to outperform, citing improvements in utilization and conservative guidance, indicating that the business has stabilized and improved recently.

Positive Outlook: The firm believes that CVRx's 2025 guidance is achievable and could drive stock growth, as utilization levels have reached their highest since 2022, with risks from previous volatility now behind them.

Preliminary Growth Expectations: CVRx, Inc. anticipates a 35% growth in Q4 and 30% for the full year 2024, with projected revenues of $15.2 million to $15.3 million for Q4 and $51.1 million to $51.2 million for the entire year.

Future Revenue Projections: The company forecasts total revenue between $63.0 million and $65.0 million for fiscal year 2025, and between $14.5 million and $15.0 million for Q1 2025, while its stock is currently trading at $14.69, up 3.71% on Nasdaq.

Fourth Quarter Revenue Expectations: CVRx anticipates fourth quarter revenue between $15.2 million and $15.3 million, marking a 35% year-over-year increase, with U.S. revenue expected to be around $14.2 million to $14.3 million.

Future Revenue Projections: For FY25, CVRx projects total revenue of $63 million to $65 million and expects operating expenses between $100 million and $104 million, while Q1 2025 revenue is estimated at $14.5 million to $15.0 million.

CVRx Presentation Announcement: CVRx, Inc. will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, at 2:15 PM Pacific Time, with a live audio webcast available on their investor relations page.

Barostim™ System Overview: The Barostim™ System is an FDA-approved medical device that uses neuromodulation to alleviate heart failure symptoms by delivering electrical pulses to baroreceptors in the carotid artery, restoring balance to the autonomic nervous system.

CVRx Presentation Announcement: CVRx, Inc. will present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 3:30 PM Eastern Time, with a live audio webcast available on their investor relations page.

Barostim™ System Overview: CVRx's Barostim™ System is the first FDA-approved neuromodulation technology for heart failure, designed to improve symptoms by delivering electrical pulses to baroreceptors in the carotid artery, and has also received CE Mark approval in Europe.

Analyst Rating Changes: Several Wall Street analysts have adjusted their price targets for various companies, including significant cuts for Estée Lauder and Wayfair, while Mastercard and Broadcom received increases in their targets.

Stock Performance: The current stock prices reflect these changes, with Estée Lauder at $66.58, Mastercard at $508.08, and Wayfair at $40.15, among others mentioned.